We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-9.61%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$216M
AUM Growth
-$53.3M
Cap. Flow
-$20.8M
Cap. Flow %
-9.59%
Top 10 Hldgs %
56.68%
Holding
66
New
2
Increased
13
Reduced
15
Closed
8

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$4.88M
2
CELG
Celgene Corp
CELG
+$2.71M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$2.33M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$2.24M
5
AMRN
Amarin Corp
AMRN
+$2.13M

Top Sells

Rank Stock Value
1
HALO icon
Halozyme
HALO
+$6.97M
2
EXEL icon
Exelixis
EXEL
+$6.88M
3
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$4.25M
4
SAGE
Sage Therapeutics
SAGE
+$3.01M
5
BIIB icon
Biogen
BIIB
+$2.56M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRPT icon
26
Sarepta Therapeutics
SRPT
$2.28B
$1.97M 0.91%
26,100
– –
RGEN icon
27
Repligen
RGEN
$10.3B
$1.84M 0.85%
24,000
– –
EXEL icon
28
Exelixis
EXEL
$13.7B
$1.83M 0.85%
103,534
-340,000
-77% -$6.88M
MYOK
29
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$1.56M 0.72%
30,000
– –
BLUE
30
DELISTED
bluebird bio
BLUE
$1.56M 0.72%
1,312
– –
ASND icon
31
Ascendis Pharma A/S
ASND
$16.4B
$1.33M 0.61%
13,800
-12,000
-47% -$1.34M
STRO icon
32
Sutro Biopharma
STRO
$353M
$1.26M 0.58%
13,933
-582
-4% -$58.8K
TPST icon
33
Tempest Therapeutics
TPST
$17.9M
$1.26M 0.58%
912
– –
BPMC
34
DELISTED
Blueprint Medicines
BPMC
$1.25M 0.58%
17,000
– –
GMED icon
35
Globus Medical
GMED
$11.1B
$1.24M 0.57%
24,200
– –
XLRN
36
DELISTED
Acceleron Pharma
XLRN
$1.18M 0.55%
30,000
– –
AGIO icon
37
Agios Pharmaceuticals
AGIO
$2.05B
$1.18M 0.55%
36,500
– –
TCDA
38
DELISTED
Tricida, Inc. Common Stock
TCDA
$1.14M 0.53%
37,000
+17,000
+85% +$569K
NKTR icon
39
Nektar Therapeutics
NKTR
$2.55B
$1.09M 0.51%
4,000
– –
QURE icon
40
uniQure
QURE
$3.44B
$1.08M 0.5%
27,500
– –
MNTA
41
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$1.04M 0.48%
80,000
– –
EXAS
42
DELISTED
Exact Sciences
EXAS
$967K 0.45%
10,700
– –
GBT
43
DELISTED
Global Blood Therapeutics, Inc.
GBT
$897K 0.41%
18,500
-9,500
-34% -$495K
MRTX
44
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$849K 0.39%
10,900
– –
HALO icon
45
Halozyme
HALO
$12.1B
$816K 0.38%
52,633
-423,000
-89% -$6.97M
ARNA
46
DELISTED
Arena Pharmaceuticals Inc
ARNA
$755K 0.35%
16,500
– –
KYNB
47
Kyntra Bio
KYNB
$32.4M
$728K 0.34%
788
– –
MYGN icon
48
Myriad Genetics
MYGN
$304M
$716K 0.33%
25,000
-15,000
-38% -$437K
DCPH
49
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$577K 0.27%
+17,000
New +$503K
ZGNX
50
DELISTED
Zogenix, Inc.
ZGNX
$577K 0.27%
14,400
– –
1
2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q3 2019 Portfolio in Review

As of Q3 2019, International Biotechnology Trust held 66 positions worth $216M, down 20% from $270M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

International Biotechnology Trust withdrew a net $20.8M in Q3 2019, closing 8 positions and reducing 15 holdings. Its most notable exit was Iovance Biotherapeutics, an estimated $2.54M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, International Biotechnology Trust opened a new position in Deciphera Pharmaceuticals, Inc. Common Stock worth $577K.

  • International Biotechnology Trust's largest Q3 2019 buy was Deciphera Pharmaceuticals, Inc. Common Stock: 17,000 shares worth $577K.
  • International Biotechnology Trust added most to Regeneron Pharmaceuticals in Q3 2019, an estimated $4.88M increase.
  • International Biotechnology Trust's biggest Q3 2019 reduction was Halozyme, cutting an estimated $6.97M.
  • International Biotechnology Trust fully exited Iovance Biotherapeutics in Q3 2019, selling an estimated $2.54M.
  • International Biotechnology Trust's ten largest holdings make up 57% of its $216M portfolio in Q3 2019.
  • International Biotechnology Trust opened 2 new positions and closed 8 in Q3 2019.
  • International Biotechnology Trust's portfolio value fell 20% quarter-over-quarter to $216M.

Based on International Biotechnology Trust's 13F filing for Q3 2019, filed 14 Nov 2019.